The Hormone Numbers That Actually Predict How Well You Age

You're 47, your bloodwork comes back "normal," and your doctor sends you home. But free testosterone is sitting at 6.2 ng/dL — technically within the lab's reference range, which bottoms out around 5 ng/dL — and your IGF-1 is at 89 ng/mL when optimal longevity research clusters it closer to 150–200 ng/mL for your age bracket. "Normal" and "optimized" are not the same thing, and the gap between them is where most people quietly lose a decade of functional health.

This is the territory that longevity-focused hormone optimization operates in — not treating disease, but closing the distance between adequate and capable.

---

Why the Standard Reference Range Is the Wrong Target

Clinical lab ranges are built from population averages, which means they include sedentary, metabolically unhealthy people across every decade of adult life. When LabCorp reports a male testosterone reference range of 264–916 ng/dL, that floor is not a goal. Traish et al. (2011, Journal of Andrology) documented that men in the lower quartile of that range show measurably worse metabolic markers, muscle mass, and cognitive performance than those in the upper quartile — even when both groups are classified as "normal."

The practical application: a 52-year-old man with total testosterone at 310 ng/dL will be told everything is fine. A well-run longevity clinic will note that his free testosterone, SHBG, estradiol, and IGF-1 together tell a different story, and that optimizing those values — not just crossing the floor — is what affects healthspan.

The same logic applies to women. Estradiol in perimenopause can swing from 10 pg/mL to over 400 pg/mL within weeks. Progesterone drops first, often precipitously, and the downstream effects — sleep disruption, cognitive fog, accelerated bone loss — predate the menopause diagnosis by years.

---

The Hormones That Get the Most Longevity Attention

Testosterone and DHEA dominate the men's optimization conversation, and with reason. DHEA-S levels decline roughly 80% between age 25 and 75. Supplementation trials, including a 2006 randomized controlled trial by Nair et al. in NEJM, showed modest but real benefits in body composition and immune function at 75–100 mg/day oral DHEA.

Growth hormone axis (IGF-1 and peptides) is the primary target for patients who want to avoid exogenous HGH. Secretagogues like sermorelin and CJC-1295 stimulate the pituitary to release growth hormone, sidestepping the suppression risks of direct GH use. A standard sermorelin protocol runs 200–500 mcg injected subcutaneously before sleep, timed to the body's natural overnight GH pulse. Expect $200–$400/month through a structured telehealth or clinic program.

NAD+ precursors (NMN, NR) and IV NAD+ infusions are now standard offerings at longevity clinics. NAD+ declines approximately 50% between age 40 and 60 in human tissue samples measured by Zhu et al. (2015, Cell Metabolism), and it sits upstream of sirtuins — the proteins most associated with cellular aging and DNA repair. The active debate is not whether NAD+ levels matter but whether oral NMN or NR translates into meaningful intracellular NAD+ recovery, given the 2023 clinical data from Pencina et al. (Nature Aging) showing NMN raised NAD+ in muscle tissue but produced only modest functional changes over 10 weeks.

Thyroid optimization is the most commonly missed lever. TSH-only testing is insufficient. Free T3 is the metabolically active hormone; patients with TSH inside the standard 0.4–4.0 mIU/L window can have free T3 at the low end of 2.3–4.2 pg/mL, which correlates with fatigue, cold intolerance, and impaired LDL clearance. A complete thyroid panel includes TSH, free T3, free T4, and reverse T3.

---

What Actually Happens in a Longevity Hormone Protocol

A serious protocol starts with comprehensive bloodwork — not a standard 10-panel, but a 60+ marker panel covering sex hormones, metabolic function, inflammation markers including hsCRP and homocysteine, and a baseline DEXA scan for body composition. Longevity clinics in Los Angeles typically charge $400–$800 for this intake; others bundle it into a first-year program fee.

Interventions are then layered. Testosterone replacement therapy for men typically begins at 100–200 mg/week of testosterone cypionate via injection, or an equivalent dose via compounded cream or subcutaneous pellet. Women's protocols start lower — 5–20 mg/week testosterone equivalent — with bioidentical progesterone cycling added based on menopausal status.

Most longevity-oriented programs also integrate peptides, lifestyle tracking, and quarterly re-testing. System Labs and Yucca Health take this bundled approach via telehealth, combining lab oversight with prescribed protocols — useful for patients who want structured monitoring without traveling to a destination clinic. For a broader survey, the longevity clinics directory indexes programs by goal and clinical approach.

---

The Risks the Optimistic Literature Undersells

Testosterone therapy raises hematocrit. Above 54%, thrombotic event risk increases — which is why hematocrit testing every three months is a clinical requirement on TRT, not an optional add-on. Exogenous testosterone suppresses endogenous LH and FSH, causing testicular atrophy and reduced sperm production; men who want to preserve fertility run HCG concurrently at 500–1,000 IU two to three times per week. Aromatization of testosterone to estradiol requires its own monitoring; estradiol above 42 pg/mL in men correlates with water retention and mood instability.

On the GH axis, secretagogues carry lower risk than direct HGH injections but are not risk-free. Fluid retention, insulin resistance, and joint pain are dose-dependent. IGF-1 elevation beyond 300 ng/mL carries theoretical cancer-promotion signals based on epidemiological data linking chronically elevated IGF-1 to colorectal and prostate cancer risk — which is why responsible longevity programs target IGF-1 in the 150–225 ng/mL range rather than maximum elevation.

---

What to Expect If You Start This

Allow 3–6 months before drawing conclusions from the data. Early TRT responders report energy and sleep improvements within 6 weeks, but body composition shifts take 3–4 months, and cognitive effects in women on HRT are typically assessed at 12 weeks per the SWAN study's tracking methodology. Protocols with quarterly labs and systematic dose adjustment produce better long-term outcomes than aggressive starting doses held flat.

The clinics worth using track your results rather than simply filling your prescription. Before committing, look at online longevity programs and ask three specific questions: what re-testing is included in the fee structure, who interprets the results, and what the dose-adjustment process looks like. Those details separate genuine optimization medicine from subscription-based TRT mills.

The goal is not maximum hormone levels. It's the profile at which you function best — and measuring that requires more than a single "normal" lab result and a handshake.

---

Peptide Clinic Finder is a comparison platform. The author may receive compensation if you sign up through links on our partner pages.

---